文献速递泌尿生殖腹部MR

前列腺MRI中央腺体体积对前列腺放疗后生化复发的预后价值

Prognostic value of central gland volume on MRI for biochemical recurrence after prostate radiotherapy.
PubMed 文献 · Abdom Radiol (NY) · 2024-11-27

回顾性单机构研究纳入373例接受根治性放疗前6个月内行前列腺MRI的患者,由放射科医生手动分割测量中央腺体体积、外周带体积及PI-RADS评分,中位随访28个月,3年和5年生化复发率分别为7.8%和18.3%。多因素Cox模型显示中央腺体体积每增加5 cc与生化复发风险降低相关(HR 0.69,95%CI 0.50-0.94,p=0.02),外周带体积、PI-RADS评分及放疗方式未见显著关联。

要点

  • 中央腺体体积每增加5 cc,生化复发风险降低(多因素HR 0.69,95%CI 0.50-0.94)。
  • 外周带体积、PI-RADS评分及放疗方式与生化复发无显著关联。
  • 中央腺体体积可能有助于放疗前患者选择和肿瘤学风险分层。

核心结论

  • 放疗前前列腺MRI上中央腺体体积增大与根治性放疗后生化复发风险降低独立相关。
  • 中央腺体体积可能改善接受放疗前的患者选择和肿瘤学风险分层。

研究设计与样本

  • 回顾性单机构研究,纳入2011年5月至2023年2月在前列腺癌数据库中完成根治性放疗前6个月内行MRI的男性患者共373例。
  • 由放射科医生手动分割测量中央腺体体积和外周带体积,并记录PI-RADS评分。
  • 主要目标为确定中央腺体体积与Phoenix标准定义的生化复发之间的关联,构建多因素Cox比例风险回归模型和逆概率加权(IPW)Cox模型。
  • 中位随访28个月;风险分组为低危13例(3.5%)、有利中危97例(26%)、不利中危201例(53.9%)、高危62例(16.6%)。
  • 放疗方式为常规分割放疗54例(14.5%)、中度大分割放疗105例(28.2%)、高剂量率近距离放疗121例(32.4%)、立体定向体部放疗93例(24.9%)。

诊断标准与关键数值

  • 生化复发采用Phoenix标准定义;3年和5年生化复发率分别为7.8%和18.3%。
  • 中央腺体体积每增加5 cc,多因素Cox模型显示生化复发风险降低(HR 0.69,95%CI 0.50-0.94,p=0.02)。
  • 中央腺体体积每增加5 cc,IPW模型显示生化复发风险降低(HR 0.75,95%CI 0.65-0.87,p<0.001)。
  • 外周带体积、PI-RADS评分及放疗方式与生化复发未见显著关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study evaluates pretreatment prostate magnetic resonance imaging (MRI) metrics and clinical characteristics in predicting biochemical recurrence (BCR) after prostate radiotherapy (RT).

METHODS: In this retrospective single institution study, we identified men in our prostate cancer database who underwent MRI within 6 months prior to completing definitive RT from May 2011 to February 2023. Central gland volume and peripheral zone volume were measured by a radiologist using manual segmentation, along with Prostate Imaging-Reporting and Data System (PI-RADS) score. The primary objective was to determine the association of central gland volume with biochemical recurrence per Phoenix criteria. Multivariable and inverse probability weighted (IPW) Cox proportional hazards regression models were constructed.

RESULTS: A total of 373 men were included, with a median follow-up of 28 months. Thirteen (3.5%) were low risk, 97 (26%) favorable intermediate risk, 201 (53.9%) unfavorable intermediate risk, and 62 (16.6%) high risk. Fifty-four (14.5%) patients received conventionally fractionated RT, 105 (28.2%) moderately hypofractionated RT, 121 (32.4%) high-dose rate brachytherapy, and 93 (24.9%) stereotactic body RT. The 3- and 5-year rates of BCR were 7.8% and 18.3%, respectively. Higher central gland volume (per 5 cc) was associated with decreased risk of BCR (hazard ratio [HR]: 0.69, 95% confidence interval [CI]: 0.50-0.94, p = 0.02) on the multivariable Cox model and IPW model (HR: 0.75, 95% CI: 0.65-0.87, p < 0.001). No significant association was seen with peripheral zone volume, PI-RADS score, or RT modality.

CONCLUSION: Increased central gland volume on pretreatment prostate MRI is independently associated with a lower risk of biochemical recurrence after definitive radiation for prostate cancer. Central gland volume may improve patient selection and oncologic risk stratification prior to offering RT.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Lee J, Salari K, Nandalur S, et al. Prognostic value of central gland volume on MRI for biochemical recurrence after prostate radiotherapy. Abdom Radiol (NY). 2024. PMID: 39592480. doi:10.1007/s00261-024-04717-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。